Aktienanalyse zu Karyopharm Therapeutics Inc (KPTI)KPTIKaryopharm Therapeutics Inc

Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of drugs directed against nuclear export for the treatment of cancer. It is developing and commercializing novel, small molecule XPO1 inhibitor compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead asset, XPOVIO (selinexor), is marketed in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. XPOVIO is also marketed for treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The Company is engaged in evaluating selinexor in certain hematological and solid tumor malignancies, including myelofibrosis, endometrial cancer and multiple myeloma. The Company’s product candidate, eltanexor, is an oral SINE compound like selinexor, that selectively blocks the nuclear export protein XPO1. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Karyopharm Therapeutics Inc is not a good buy right now due to significant financial losses and declining revenues. The current price is $1.87, with a 1-year change of -72.42%. The company reported a net loss of $67 million for Q2 2026, which is a substantial increase from the previous year's loss of $37.25 million. Additionally, there is a liquidity risk with only $65.4 million in cash, expected to be exhausted by September 2026, posing a serious threat to its operational viability.

11 analysts cover KPTI: 10 rate it Buy, 0 Hold and 1 Sell. The average price target is 13.83.